XML 27 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1
REVENUE
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
 The following table presents the Company’s revenues disaggregated by revenue source:
Year Ended December 31,
(In thousands)202420232022
Screening
Medicare Parts B & C$776,155 $701,400 $545,458 
Commercial1,118,338 992,244 743,238 
Other209,375 171,057 136,007 
Total Screening2,103,868 1,864,701 1,424,703 
Precision Oncology
Medicare Parts B & C$187,948 $188,689 $197,327 
Commercial190,595 181,318 177,518 
International189,092 153,277 117,738 
Other87,364 105,826 108,905 
Total Precision Oncology654,999 629,110 601,488 
COVID-19 Testing$— $5,955 $58,088 
Total$2,758,867 $2,499,766 $2,084,279 
Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics tests while Precision Oncology revenue primarily includes laboratory service revenue from global Oncotype DX and therapy selection tests. The Company discontinued its COVID-19 testing operations in the second quarter of 2023.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. Adjustments to revenue recognized during the period relating to prior period estimates were less than 1%, 2%, and 1% of revenue recorded in the Company’s consolidated statement of operations for the years ended December 31, 2024, 2023, and 2022, respectively.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s consolidated balance sheets, was not significant as of December 31, 2024 and 2023.
Revenue recognized for the years ended December 31, 2024 and 2023, which was included in the deferred revenue balance at the beginning of the year was not significant.